Integer Holdings Corporation Common Stock (ITGR)

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 13.2%. This drawdown was noticeably worse than the S&P 500’s 2.4% loss.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Medical technology company Integer Holdings (NYSE:ITGR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 7.3% year on year to $437.4 million. The company expects the full year’s revenue to be around $1.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.31 per share was 5.5% above analysts’ consensus estimates.

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know.

Medical technology company Integer Holdings (NYSE:ITGR) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.3% year on year to $437.4 million. The company expects the full year’s revenue to be around $1.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.31 per share was 5.5% above analysts’ consensus estimates.

Medical technology company Integer Holdings (NYSE:ITGR) will be reporting earnings tomorrow before market hours. Here’s what you need to know.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.

The Russell 2000 is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Integer Holdings trades at $113.57 per share and has stayed right on track with the overall market, losing 11.4% over the last six months while the S&P 500 is down 7.7%. This may have investors wondering how to approach the situation.

Let’s dig into the relative performance of Integer Holdings (NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including STAAR Surgical (NASDAQ:STAA) and its peers.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and worst performers in the medical devices & supplies - specialty industry.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry.